Articles tagged with Adjuvants
The American Society for Radiation Oncology has updated its treatment standard for rectal cancer, recommending a more customized approach that may reduce treatment side effects. The new guideline suggests alternatives to the traditional tri-modal approach, including short-course radiation therapy and non-operative management.
Researchers at Jackson Laboratory aim to develop clinical adjuvants that boost vaccine effectiveness in vulnerable populations, with a focus on elderly and immunosuppressed patients. The $3.4 million grant will support the screening of new adjuvant combinations and investigation into their mechanisms of action.
A large cohort of 29,908 patients with pathologic stage T2N0M0 NSCLC showed improved median overall survival and 5-year OS when receiving adjuvant chemotherapy. The study demonstrated a benefit from adjuvant chemotherapy in patients with completely resected stage T2N0M0 NSCLC regardless of tumor size.
The NIH has awarded six grants to study the molecular mechanisms behind combination vaccine adjuvants, which improve vaccine effectiveness and could lead to new treatments for diseases like HIV and tuberculosis. Researchers will explore how individual adjuvants work in combination and how synergies between them can be optimized.
Researchers found that dose-dense adjuvant chemotherapy significantly improved overall survival after ten years by nearly a third compared to standard interval regimens. Dose-dense chemotherapy was not associated with an increased risk of treatment-induced amenorrhea, and it seemed effective irrespective of hormone receptor status.
Researchers found a promising adjuvant, chitosan, induces immune response through a DNA-sensing pathway in cells. This discovery provides a roadmap for developing vaccines that trigger 'cell-mediated immunity',
A new study suggests that patients with resectable pancreatic cancer should receive at least 6 months of adjuvant chemotherapy to reduce distant disease recurrences and improve overall survival. Chemotherapy, but not chemoradiotherapy, significantly reduces the incidence of distant recurrence.
Researchers developed an infant-friendly flu vaccine using a natural protein that provides four to five times the protection against influenza compared to traditional adjuvants. This breakthrough could lead to safer and more effective vaccinations for premature infants.
The ABCSG-18 clinical trial found that adding denosumab to adjuvant aromatase inhibitor therapy improved disease-free survival in postmenopausal patients with HR+ breast cancer. After a median follow-up of four years, patients assigned denosumab had an 18 percent reduced risk of disease recurring compared with those assigned placebo.
A new study found that breast cancer adjuvant therapies have varying effects on patients over time. Researchers analyzed 19 clinical trials and discovered nearly half showed time-varying treatment effects.
Australian researchers have found a way to boost influenza A vaccine effectiveness by adding an adjuvant, which stimulates both innate and adaptive immunity. The additive provides cross-protective capabilities, reducing the ability of the virus to infect cells and spread.
A phase 2 trial found that AS03 and MF59 adjuvants increased immune responses to an inactivated H7N9 influenza vaccine, with AS03-adjuvanted formulations inducing the highest antibody response. The study suggests AS03 as a first-line adjuvant for H7N9 vaccines in adults.
A new vaccine has been developed that generates double protection against chlamydia by teaching the immune system to recognize and remember the bacteria as a threat. The vaccine uses charge-switching synthetic adjuvant nanoparticles to bind to the bacteria, targeting mucosal surfaces and inducing an immune response.
A recent EORTC trial found that adjuvant Ipilimumab significantly improves recurrence-free survival in patients with completely resected stage III melanoma at high risk of disease recurrence. However, the treatment was also associated with a high rate of immune-related adverse events.
The use of adjuvant systemic therapy for localized gastrointestinal stromal tumors (GISTs) has significantly increased over time, leading to better survival rates among treated patients. The study found that older patients and minorities are less likely to receive this therapy.
A live attenuated ETEC vaccine candidate given with a novel adjuvant provided significant protection against disease, with a 58.5% efficacy rate against diarrhea of any severity. The vaccine also showed protective efficacy of 65.9% against severe ETEC diarrhea.
Researchers will screen tens of thousands of chemical molecules to identify effective adjuvants for vaccines against infectious diseases. The project aims to develop novel applications for enhancing the immune response against Ebola virus, HIV, and other virus infections.
Researchers found that clove oil herbicide did not consistently improve weed control in organic Vidalia sweet onions. The study concluded that the herbicide was not effective enough to justify its expense due to issues with maintaining an emulsion and affecting onion yield.
A large clinical trial found that an H7N9 flu vaccine mixed with an adjuvant provided a protective immune response in 59% of participants. The addition of the adjuvant enhanced the effectiveness of the vaccine, even at lower dosages.
A new experimental vaccine against H7N9 avian influenza prompted immune responses in 59% of volunteers who received two injections with an adjuvant booster. Without the adjuvant, immune responses were minimal regardless of vaccine dosage.
Researchers examined new vaccination strategies to combat avian flu, finding that MF59 adjuvant improves immunogenicity and enhances efficacy. The studies also showed that prior exposure to a related antigen can lead to increased antibody responses to subsequent vaccinations.
The National Institute of Allergy and Infectious Diseases has awarded seven research contracts to discover novel vaccine adjuvants that safely boost immune responses. The goal is to improve current vaccines, extend the vaccine supply, or enhance efficacy in people with immature or weakened immune systems.
Researchers at Technical University of Munich have discovered a new site where T lymphocytes can be programmed to attack pathogens. The liver plays a key role in this process, and synthetic messenger Hyper-IL-6 has been found to efficiently activate T cells, offering a promising new adjuvant for vaccine formulations.
A retrospective analysis of adjuvant chemotherapy's impact on overall survival in patients with stage III soft tissue sarcomas (STS) found a significant benefit. Patients treated with adjuvant chemotherapy had an improved median overall survival, with a 23% increase compared to those not treated.
The EORTC will present nine abstracts at the ASCO 2014 Annual Meeting, highlighting significant findings in bladder cancer, melanoma, and soft tissue sarcoma. The studies show improvements in progression-free survival for patients with muscle-invasive bladder cancer and adjuvant chemotherapy efficacy in melanoma.
Polymeric vaccine adjuvants in nanoparticles, matrices, or micelles can prompt strong adaptive immune responses. Researchers summarize the benefits and challenges of these polymer systems as adjuvants in vaccines.
A new adjuvant, IL-33, enhances the immune response to cancer cells and viruses. The protein is being studied as a potential boost for vaccines against pathogens.
Researchers found that a new adjuvant improved flu vaccine effectiveness in mice and showed promise for the elderly. The study also highlighted the importance of characterizing immune responses following intra-nasal vaccinations, particularly with novel adjuvants.
A 10.4-year median follow-up study by EORTC trial 22921 found that adjuvant chemotherapy does not improve survival or disease-free survival for cT3-resectable T4 M0 rectal cancer patients, highlighting the need for new treatment strategies.
A new study has identified a highly effective treatment option for patients with HER2-positive breast cancer, combining docetaxel, carboplatin, and trastuzumab. The treatment regimen demonstrates improved outcomes and a safer profile compared to anthracycline-based therapies, which are currently dominated in breast cancer treatment.
Pretreating intradermal vaccination with near-infrared laser light improves vaccine effectiveness by increasing immune system activity and survival rates in a mouse model. The treatment also increases antibody production and dendritic cell concentrations, indicating a safe alternative to chemical adjuvants.
A study by researchers from the Mount Sinai Hospital found that nearly 80% of women who contacted a patient assistance program had their needs met, compared to just 35% of those who did not. Most patients utilized programs for information about adjuvant therapies, psychosocial support, and overcoming practical/financial obstacles.
A new research project will develop the next generation of effective mucosal vaccines using immunomodulation and cell-targeted nanoparticles. This innovation aims to improve vaccine administration in resource-poor settings, reducing blood-borne contamination and pandemic spread risks.
The EORTC 62024 trial found that adjuvant imatinib impacts short-term freedom from relapse in patients with localized, surgically resected, high/intermediate-risk GIST. The trial showed a non-statistically significant trend in favor of the adjuvant arm for Imatinib failure-free survival.
Researchers at National Jewish Health discovered that alum, a common vaccine adjuvant, works by coating with host DNA, inducing T cells to interact longer with the vaccine, resulting in a stronger immune response. This breakthrough could lead to more effective vaccines and improved public health outcomes.
A prospective study found that children with low-risk retinoblastoma do not need postoperative chemotherapy to prevent disease recurrence or metastasis. The results suggest that certain patients with intermediate-risk disease can receive less aggressive adjuvant treatment or even forego it altogether.
UT MD Anderson scientists found that a common substance in cancer vaccines facilitates a buildup of T cells at the vaccination site, summoning more T cells and causing lesions. Switching to saline adjuvant reversed the effect, allowing T cells to target tumors. A new clinical trial is expected to test this concept.
Researchers have developed 61 new strains of genetically engineered bacteria that can boost the immune response to vaccines. The bacteria are designed to express endotoxin molecules in different configurations, creating a range of potential adjuvants for vaccine design.
A study by Yale University researchers found that older women with breast cancer treated with adjuvant trastuzumab are at a higher risk of heart failure or cardiomyopathy. The use of trastuzumab was associated with a 14% increased incidence rate of heart failure over three years.
Researchers have discovered a potent adjuvant that enhances the immune response to vaccines against HIV, flu, and herpes. The compound, polyethyleneimine (PEI), shows promise in mice, offering improved protection against these difficult-to-tackle diseases.
The trial aims to evaluate the safety and immunogenicity of the H5N1 vaccine combined with IDRI's GLA adjuvant, which may result in a self-administered flu vaccine. The collaboration has the potential to expedite vaccination and simplify distribution during a pandemic.
A recent study suggests a positive correlation between tumor size and chemotherapy efficacy in surgically resected patients with node-negative non-small cell lung cancer. The study found no clear threshold for tumor size that correlated with a benefit from chemotherapy.
GW researchers are evaluating innovative methods to assess the immune response to vaccines with a novel Toll-like Receptor (TLR)-4 agonist adjuvant. They will use new antibody profiling techniques to determine the quality of the humoral immune response in humans.
Patients with high-risk GI tumors who received imatinib for 3 years instead of 1 year had improved recurrence-free survival and overall survival. The study found that longer treatment with the cancer drug resulted in better survival outcomes and fewer patients discontinued treatment due to adverse effects.
A Dutch study reveals that breast cancer screening and improved treatments together save a significant number of lives. The study found that adjuvant therapy reduced deaths by 13.9%, while two-yearly screening added another 15.7%. Combining both approaches resulted in a total reduction of 31.1% in breast cancer mortality.
A new lung cancer assay measures gene activity in tumor tissue and provides a risk score to predict patient survival after surgery. The assay has been validated in two independent trials and shows promise in identifying patients at highest risk of mortality.
Scientists at Duke University Medical Center created nanoparticles that target lymph nodes to greatly enhance vaccine responses. The particles mimic natural mast cell granules and provide a timed release of inflammatory mediators, stimulating effective immune reactions in mice vaccinated with the influenza A virus.
A recent study found that adding oxaliplatin to adjuvant chemotherapy for stage III colon cancer patients in the general population improved overall survival rates. The research also showed that this combination therapy was effective across various practice settings, including older and minority patients with comorbid conditions.
A new predictive tool has been developed to assess the risk of recurrence in gastrointestinal stromal tumours (GIST) following surgery. The tool provides more accurate prognosis for individual GIST patients compared to conventional models, helping to identify those most likely to benefit from additional treatment.
Researchers found that low-risk patients aged 60 or older with small tumors and low-grade disease have mortality rates comparable to the general population. These patients may not benefit from adjuvant therapy, contradicting previous recommendations for almost all patients with hormone-responsive disease.
A new study by Thomas Jefferson University researchers finds that receiving radiation therapy immediately after a radical prostatectomy is a cost-effective treatment for prostate cancer patients. Urologists were less likely than radiation oncologists to recommend adjuvant radiation therapy or believe it improves overall survival.
A combination of two adjuvants induces CD8 killer T cells to join antibodies in response to influenza infection, potentially boosting vaccine effectiveness. The strategy has promise for a universal flu vaccine that wouldn't require annual reformulation.
A new vaccine approach using an adjuvant to stimulate the immune system shows promise in a study of Gambian infants, highlighting potential for single-shot protection at birth and reducing immunizations needed. The study's findings could have major wins for global health.
A new study found thalidomide significantly increased two-year disease-free survival rate (65%) compared to placebo (33%). However, overall survival rates were comparable between treatment groups. This finding provides new hope for difficult-to-treat liver cancer patients.
Alum, a common vaccine adjuvant, interacts with dendritic cells to activate T cells that control antibody production. The breakthrough study uses single cell force spectroscopy to understand alum's properties, potentially leading to new vaccines for major diseases.
Researchers at Boston University School of Medicine found that patients with invasive T3 and T4 non-small lung cancer who received chemotherapy before surgery had a significantly improved survival rate. The study, published in the Journal of Thoracic and Cardiovascular Surgery, showed that median survival was greatest for those who rec...
The AZURE trial, involving 3,360 patients, explores the effects of zoledronic acid on disease-free survival and secondary outcomes in Stage II/III breast cancer. The results will provide valuable insights into the benefits of combining zoledronic acid with adjuvant endocrine therapy.
Research suggests that most women with small HER2-positive breast cancers could benefit from trastuzumab treatment due to the favorable prognosis and low risk of recurrence. The authors recommend discussing the benefits and risks of adjuvant trastuzumab with patients.
A study of Italian women with breast cancer found that most cases were diagnosed in people over 50 and had not spread to lymph nodes. The disease was hormone-receptor positive and HER2-negative, indicating a classical endocrine-responsive type. Treatment choices were influenced by tumor stage rather than biological factors.
A study published in JAMA found that gemcitabine was not superior to fluorouracil plus folinic acid in terms of overall survival for patients with resected pancreatic cancer. The study included 1,088 patients and showed no significant difference in survival estimates between the treatment groups.